Gastric Electrical Stimulation
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.40 alerts
Get alerted when Policy CP.MP.40 changes without checking for updates manually.
Monitor payer policy activity
Criteria and coding guidance for coverage of gastric electrical stimulation for gastroparesis for health plans affiliated with Centene Corporation, governing clinical medical necessity and exclusions for enrolled members and provider billing.
No material clinical or coverage changes in this revision.
Coverage Criteria for Gastric Electrical Stimulation
Initial Therapy/Covered Indication
Covered when ALL of the following are met
Recommended combination prokinetic therapy includes metoclopramide and erythromycin; centrally acting antidepressants may be used as symptom modulators
Use limited to HDE-specified indications and institutional IRB oversight as applicable
GES is covered only when the medical necessity criteria in this policy are met. Use of gastric electrical stimulation for indications not supported by the evidence is considered outside the scope of coverage. Specifically, GES is not medically necessary for reduction of pain, fullness, bloating, or acid reflux, and current evidence does not support its use for other indications including treatment of obesity.
Requests for GES when intended to treat symptoms other than nausea and vomiting (for example, pain, early satiety/fullness, bloating, or acid reflux) should be denied as not medically necessary because there is no evidence to support benefit. Similarly, use of GES for the treatment of obesity or any other non–evidence‑based indication is considered not medically necessary.
Procedure and Supply Codes
| 43647 | Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum. |
| 43648 | Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum. |
| 43881 | Implantation or replacement of gastric neurostimulator electrodes, antrum, open. |
| 43882 | Revision or removal of gastric neurostimulator electrodes, antrum, open. |
| 64590 | Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver. |
| 64595 | Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array. |
| 95980 | Electronic analysis of implanted neurostimulator pulse generator system, gastric neurostimulator pulse generator/transmitter, intraoperative, with programming. |
| 95981 | Electronic analysis of implanted neurostimulator pulse generator system; subsequent, without reprogramming. |
| 95982 | Electronic analysis of implanted neurostimulator pulse generator system; subsequent, with reprogramming. |
| C1767 | Generator, neurostimulator (implantable), non-rechargeable. |
| L8679 | Implantable neurostimulator, pulse generator, any type. |
| L8680 | Implantable neurostimulator electrode, each. |
| L8685 | Implantable neurostimulator pulse generator, single array, rechargeable, includes extension. |
| L8686 | Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension. |
| L8687 | Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension. |
| L8688 | Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension. |
Provider Requirements, Prior Authorization, and Denials
Prior Authorization Required
Prior authorization is required for implantation, revision, removal, pulse generator procedures and associated HCPCS/CPT supplies for gastric electrical stimulation (GES). Requests must include documentation that the member meets medical necessity criteria (age, diagnostic confirmation, chronic drug‑refractory symptoms, and prior therapy trials).
Required Medication / Dietary Therapy Trials
A trial and documented intolerance or failure of combination prokinetic and antiemetic therapy plus dietary modifications is required prior to approval of GES. Current recommended combination prokinetic therapy includes metoclopramide and erythromycin; centrally acting antidepressants may be used as symptom modulators. Documentation must show trial duration, agents tried, reasons for intolerance or failure, and that dietary modification efforts were attempted.
- Required medication trial: combination prokinetic (e.g., metoclopramide + erythromycin) and antiemetic therapy
- Required adjuncts: dietary modifications and use of centrally acting antidepressants as symptom modulators where applicable
- Documentation: dates of trials, dosages, response, and documented intolerance or failure
Denial Triggers for Unmet Medical Necessity Criteria
Requests will be denied when medical necessity criteria are not met. Denial triggers include: member < 18 years old; no gastric emptying scintigraphy confirming diabetic or idiopathic gastroparesis; symptoms not chronic intractable (not drug‑refractory); lack of documented trial and failure/intolerance of antiemetic, prokinetic therapy and dietary modifications; current pregnancy; or device use outside the FDA Humanitarian Device Exemption (HDE) specifications. GES requested for unsupported indications (reduction of pain, fullness, bloating, acid reflux, obesity, or other non‑supported indications) is not medically necessary and may be denied.
- Denial triggers: age < 18, no confirmatory gastric emptying scintigraphy for diabetic/idiopathic gastroparesis
- Denial triggers: symptoms not documented as chronic intractable (drug‑refractory) or lack of documented failed/intolerant trials of required therapies
- Denial triggers: pregnancy or request for indications outside HDE (including pain, fullness, bloating, reflux, obesity)
- Operational note: include clear medical record documentation of trials, diagnostic testing, symptom history, and pregnancy status to avoid denial
Key Definitions
Background on Gastroparesis and GES
Gastroparesis is delayed gastric emptying without mechanical obstruction and most commonly occurs in idiopathic and diabetic forms. Patients typically present with nausea and vomiting and may also experience early satiety, bloating, and abdominal discomfort; these symptoms can lead to weight loss and malnutrition. Gastric electrical stimulation (GES) involves implantation of leads into the gastric muscularis connected to a subcutaneous pulse generator to deliver electrical stimulation aimed primarily at reducing refractory nausea and vomiting, although it typically does not normalize gastric emptying and is intended for symptom control in selected, treatment‑refractory patients.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.